1.70
전일 마감가:
$1.47
열려 있는:
$1.82
하루 거래량:
15.68M
Relative Volume:
9.38
시가총액:
$1.07M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00203
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
+42.28%
1개월 성능:
-37.50%
6개월 성능:
-68.47%
1년 성능:
-93.97%
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
BDRX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BDRX
Biodexa Pharmaceuticals Plc Adr
|
1.71 | 1.07M | 644.60K | -9.87M | -9.02M | -837.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.53 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
581.02 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
556.38 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
240.50 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
240.24 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-02-08 | 개시 | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Barchart.com
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater
Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News
Interim results for the six months ended June 30, 2024 - StockTitan
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
ADR Ratio Change - GlobeNewswire
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
Biodexa secures full access to cancer research grant - Investing.com
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):